Evaluation of the fragility of pivotal trials used to support FDA approval for plaque psoriasis: Supplementary Figures and Tables

Published: 30 August 2020| Version 1 | DOI: 10.17632/5sxhn6hn6g.1
Contributors:
,
,
,

Description

Supplementary Tables 1- 4, Supplementary Figures 1- 3

Files

Institutions

Harvard Medical School, Massachusetts General Hospital Cancer Center

Categories

Therapeutics, Randomized Controlled Trial, Psoriasis

Licence